Daily Stocks Briefing: Anthropic's $3.4bn generator deal lifted Caterpillar and led industrials to the top of Monday's rally, while TransDigm shows that even the widest moat cannot justify every price.

Top 3 takeaways

AI power demand is now an industrials story, not only a utilities story. Caterpillar rose about 7% after the FT reported Anthropic took over a $3.4bn, 1.7 GW order of Caterpillar gas generators. Constellation Energy jumped 10.5% on a beat-and-raise. Industrials led all S&P 500 sectors. Buyers with power needs are paying up for equipment that is already built.

TransDigm is down about 4% before the open even though it beat. Its fiscal 2027 adjusted EPS guidance of $47.09–47.94 sits below the ~$48.66 consensus, while sales guidance beat. When a compounder trades near record valuations, a guide that is merely "good" gets sold. The moat itself is unchanged.

GLP-1 makers get a class-wide eye-risk warning; the market shrugged. The FDA is requiring a NAION (optic nerve) warning on all GLP-1 labels, including Lilly's Zepbound and Novo's Wegovy. Lilly still rose on Monday. Because the warning applies to every drug in the class, it does not shift share between Lilly and Novo. The bigger risk is the litigation it supports.

Market snapshot

US figures are Monday 9 Nov closes. Sector figures use the SPDR sector ETFs as proxies (CappNotes closing recap). The Motley Fool's close puts industrials at +4.59% instead of +3.82%. The Stoxx 600 close varies by source, so a range is given.

Futures early Tuesday: S&P 500 about +0.2%. The Stoxx 600 opened about +0.9% at 662.54, near a record (Reuters via MarketScreener).

Wide-moat compounders

Caterpillar: Anthropic pays up for generators that are already on order

What happened:

• The Financial Times reported that Anthropic agreed in late September to pay about $3.4bn for 1.7 GW of heavy-duty gas generators. It took over orders that San Antonio-based OnePWR Solutions had placed with Caterpillar about two years ago but could not finance. Anthropic did not buy OnePWR. The deal includes engineering and installation work (FT via Quartz, Tom's Hardware, MLQ).
• Caterpillar rose 6.6% (GuruFocus) to 7.2% (CappNotes close) on Monday and was one of the main drivers of the Dow's 1,104-point gain (CNBC).
• Reports describe a waitlist of up to six years for large gas turbines and generators. Anthropic avoided that wait by buying a place in line.

Moat and growth check: This supports the long-term thesis. Caterpillar's moat rests on its dealer and service network and its installed base, and power generation is now its fastest-growing end market. The deal does not add new Caterpillar orders, because the units were already in the backlog. What it does show is that the backlog is real and that AI buyers will pay to step into stalled orders. That reduces cancellation risk across the industry.

Is the market over- or under-reacting? Our view: A 7% move for orders that were already booked looks generous on the numbers alone. The re-rating is really about confidence. Last week, after the midterms, investors worried that state permit fights would stall data center spending. A frontier AI lab committing $3.4bn to on-site gas power is a direct answer: if the grid is slow, buyers will build their own power. That favors equipment makers over grid-dependent developers.

Winners and losers: Winners: Caterpillar, other on-site power suppliers (Cummins, Rolls-Royce's power systems unit, Bloom Energy, which rose more than 13%), and gas turbine makers with long backlogs (GE Vernova, Siemens Energy). Losers: smaller equipment buyers who cannot outbid AI labs for scarce capacity, and the environmental case for data centers, which will attract more criticism.

TransDigm beats and guides higher, but not by enough for its valuation

What happened:

• Fiscal Q4 net sales rose 23% to $2,988m, with 14% organic growth. Adjusted EPS was $12.44 versus about $12.15–12.22 expected. Both sales and EBITDA came in above the top of guidance (TransDigm release; AP; Investing.com).
• Fiscal 2027 guidance: net sales of $11.95–12.15bn (consensus ~$11.75bn), EBITDA As Defined of $6.195–6.345bn (+13% at midpoint, ~52% margin) and adjusted EPS of $47.09–47.94 versus a ~$48.66 consensus (Investing.com). Assumptions: commercial OEM growth in the high single digits to low double digits, aftermarket and defense growth in the high single digits.
• Fiscal 2026 buybacks hit a record $2.8bn (2.3m shares at an average of $1,187), and the company spent about $4.4bn on acquisitions. No special dividend was declared.
• Shares fell about 4% in pre-market trading (Investing.com).

Moat and growth check: The moat is intact. About half of TransDigm's revenue comes from aftermarket parts it alone supplies, which is where its pricing power and ~53% EBITDA margins come from. The margin dip to about 52% guided for 2027 reflects lower-margin acquisitions, not a loss of pricing power. This is a one-quarter valuation story, not a change in the thesis.

Is the market over- or under-reacting? Our view: The selloff is about the starting point. At the Q4 average buyback price of about $1,150, the stock trades near 24x the midpoint of 2027 adjusted EPS guidance (our estimate). TransDigm habitually guides conservatively and then raises, so the EPS gap of about 2% is likely to close during the year. The real watch item is interest costs: with roughly $25bn of debt (our estimate), higher rates eat directly into EPS. A December Fed hike is about 80% priced.

Winners and losers: A cautious outlook from the most aggressive pricer in aerospace is mildly reassuring for airlines and lessors facing higher parts costs. For peers such as HEICO and Safran's aftermarket business, it confirms that aftermarket demand is still healthy (high single-digit growth guided).

Berkshire Hathaway: Abel more than doubles buybacks as insurance profits slip

What happened:

• Q3 operating earnings fell about 6% to ~$12.7bn. Insurance underwriting profit fell 26%, and GEICO's pretax result fell 45%. Railroad earnings rose 19% (Reuters via GV Wire; StockAnalysis; Finimize).
• Berkshire bought back $9.6bn of stock in the quarter, up from $4.5bn in Q2. Cash and equivalents were $356.9bn (Reuters); Bloomberg counts $377.4bn including the railroad, the utilities and unsettled T-bills.
• The stock dipped 0.4% on Monday, its first trading session after the Saturday release, in a market that rose more than 2% (CNBC).

Moat and growth check: The thesis is unchanged, but the way capital is allocated is changing. Under Greg Abel, Berkshire buys back stock more readily (it also paid $6.8bn for Taylor Morrison in July). The weak insurance result looks cyclical: auto insurance pricing is softening after two very profitable years. It does not point to a lost moat.

Is the market over- or under-reacting? Our view: Lagging a strong market on a day of risk-on buying is normal for Berkshire. Buybacks of $9.6bn are a clear signal that management thinks the shares trade below intrinsic value. The cash pile still earns well in a rising-rate world, so the Fed's hikes help Berkshire's interest income.

Winners and losers: GEICO's weaker result points to a softening auto insurance cycle. That is a headwind for Progressive and Allstate margins in 2027 and good news for drivers' premiums.

Other compounder notes

• KKR rose 1.7% after record per-share results: fee-related earnings rose 27% to $1.3bn ($1.42 per adjusted share), and assets under management reached $804bn (+11%) (KKR 8-K; CappNotes). Higher management fees across private equity, real assets and credit drove the gain. Our view: Fee earnings growing faster than assets shows pricing power in private markets, despite worries about AI-related private credit.
• Royal Bank of Canada rose 1.5% after agreeing to buy Australia's Yarra Capital Management (CappNotes).

High-growth leaders

Constellation Energy jumps 10.5% as its guidance raise answers the skeptics

What happened:

• Q3 adjusted operating EPS was $5.06 versus about $3.90 expected and $3.04 a year earlier. Revenue rose about 45% to $9.55bn, mainly because of the Calpine acquisition (closed January 2026) (Constellation 8-K; GuruFocus).
• 2026 guidance rose to $12.50–12.80 from $11.50–12.50, the second raise this year. Before the release, consensus of $11.72 sat in the lower half of the old range.
• Constellation signed a 20-year power purchase agreement with Google that supports more than $4.3bn of investment in uprates at 11 reactors, adding about 890 MW to the PJM grid.
• The stock closed +10.5% at $276.09. It is still well below its 52-week high of $380.78 and down about 21% over 12 months. NRG Energy rose about 10.3% on results and a $4bn asset sale (CappNotes; StockTitan).

Moat and growth check: This strengthens the long-term case. The Google deal shows how growth will come: uprates at existing nuclear plants are the fastest and cheapest way to add firm, carbon-free power, and Constellation owns the largest fleet. Long-term contracts with hyperscalers turn volatile power prices into contracted, utility-like cash flows.

Is the market over- or under-reacting? Our view: A 10% jump after a 35% drawdown looks like a repricing of the risk, not euphoria. At $276, the stock trades about 22x the midpoint of 2026 guidance (our estimate). The Senate's permitting bill, which cleared a 73–25 procedural vote on Monday, would make large data centers pay for grid upgrades. That favors generators that sell power under long contracts. The risk is political: price caps and state limits on data center power deals in PJM.

Winners and losers: Winners: nuclear operators (Vistra, Talen) and uprate suppliers (Westinghouse, BWX Technologies, Curtiss-Wright). Losers: PJM customers facing higher capacity prices, and developers that depend on new grid connections.

GLP-1: a class-wide eye warning, Lilly unbothered, Hims stumbles

What happened:

• On 9 Nov the FDA required all GLP-1 drugs, including Lilly's Mounjaro and Zepbound and Novo's Ozempic and Wegovy, to add a warning about NAION, a rare optic nerve condition that can cause permanent vision loss in one eye. Doctors should consider stopping treatment in affected patients unless the benefits "clearly outweigh the risk" (CNN; Bloomberg; Drugwatch). Lilly said the communication applies to the whole class and contains no findings specific to its drugs.
• Europe, the UK and Australia added similar warnings in 2025. Thousands of lawsuits alleging vision loss are already consolidated in US courts (Review of Optometry).
• Lilly rose on Monday (about 2% pre-market, and about +3.7% midday per MarketBeat data), helped by a positive recommendation from Canada's drug agency for its Alzheimer's drug Kisunla (CNBC).
• Hims & Hers reported Q3 revenue of $890m (+49%), in line, but an adjusted loss of $0.14 per share versus a profit expected. Gross margin fell to 57% from 74% because of a higher mix of lower-margin GLP-1 products. Q4 revenue guidance of $875–895m missed the ~$954m consensus. The stock fell about 2% pre-market (CNBC; GuruFocus; Hims release).

Moat and growth check: The warning does not change the GLP-1 thesis. The condition is rare (Europe's label puts it at up to 1 in 10,000), the class benefits are large, and the warning applies to everyone. That means no share shifts between Lilly and Novo. The Hims result shows the opposite side of the moat: telehealth resellers of GLP-1s carry low margins and depend on branded makers' pricing.

Is the market over- or under-reacting? Our view: The market is right to look through the label change. US warnings were widely expected since the FDA flagged the signal in March 2025. The second-order effect is legal: an FDA warning strengthens plaintiffs' "failure to warn" claims for past use, which could mean a long tail of litigation costs for Novo (semaglutide has the longest history). That is a headline risk, not a threat to the franchise.

Winners and losers: Lilly remains the clear leader. Its market value is now almost nine times Novo's (Motley Fool). Exposed: Hims and compounding-based telehealth models, whose margins are under pressure as branded makers sell directly to consumers.

On Holding: strong growth, but the profit beat came from a tariff refund

What happened:

• Q3 net sales rose 17.2% to CHF 931.4m (+17.8% in constant currency), slightly above consensus. DTC sales rose 25%; APAC rose 31%; the Americas, its largest region, rose 12.4%. Apparel rose 38.7% (On Holding 6-K).
• Gross margin reached 72.6%, but CHF 52.6m of US tariff refunds flattered it. Excluding the refunds, it was 66.9%. Adjusted EPS of CHF 0.54 beat the CHF 0.38–0.39 consensus, again helped by the refund.
• Guidance: constant-currency sales growth in the "low-20% range" is unchanged. The underlying gross margin target rose to ~66% (from at least 65%). The underlying adjusted EBITDA margin of 19.5–20.0% is unchanged.
• Shares fell 4–5% before the open (Investing.com).

Moat and growth check: The brand moat looks healthy. A 66.9% underlying gross margin at this growth rate shows real pricing power, and the shift toward DTC and apparel lengthens the runway. The weak spot is the Americas: 12% growth there is the slowest of its regions.

Is the market over- or under-reacting? Our view: The selloff targets the quality of the beat, not the business. Investors wanted an upgrade to underlying profit guidance and did not get one. On still needs about 20%+ growth in Q4 to reach the low-20% full-year target in constant currency, so the fourth quarter carries the year.

Winners and losers: Read-through for premium sportswear (Deckers' Hoka, Amer Sports): China and Asia demand for premium running remains strong, while US growth is slowing. Tariff refunds may also flatter other importers' results this quarter.

Biotech quick hits

• Vir Biotechnology rose 11.8% after its Phase 3 hepatitis delta trial met its primary endpoint (StockTitan).
• Ionis fell 21.4% after cutting its 2026 sales forecast for Tryngolza to about $50m, a sign that launches in rare diseases can be slow (StockTitan).
• argenx will buy Unnatural Products for up to $1.15bn, adding a macrocyclic peptide platform. It is a bet on oral drugs to extend its immunology franchise beyond Vyvgart (argenx; BioXconomy).
• Acadia fell 22.3% after its Phase 2 Alzheimer's psychosis study missed its primary endpoint (CappNotes).

Sector rotation & themes

Industrials and small caps led a broad rally; defensives lagged

• Every S&P 500 sector rose. Industrials led (+3.8% to +4.6% depending on the source), followed by consumer discretionary (+2.9%). Consumer staples (+0.9%) and energy (+0.5%) lagged (CappNotes; Motley Fool; CNBC).
• The Russell 2000 rose 3.15% and the S&P MidCap 400 3.13%, both beating the S&P 500's 2.35%. Breadth was strong: about 423 S&P 500 stocks rose and 78 fell (CappNotes).
• Cheaper oil lifted travel: Brent settled down 5.85% at $92.57. American and United rose more than 6%, Delta 4.6%, Carnival 4%, and Royal Caribbean and Norwegian more than 3% (CNBC).
• Industrial results also helped: CNH Industrial rose about 10.9% on a beat and raised outlook, and QXO rose about 19% on preliminary Q3 sales up 79% (CappNotes; StockTitan).
• Our view: This is a cyclical, risk-on rotation driven by cheaper oil and relief over data center demand, not a flight to quality. Staples' lagging shows money left defensives. Whether it holds depends on today's CPI: cheaper oil helps headline inflation, but the Fed is focused on core. A +0.3% core reading would hit small caps hardest.

European banks: Crédit Agricole bids for Banco BPM as UniCredit posts a record

What happened:

• Crédit Agricole proposed merging its Italian unit, Crédit Agricole Italia, into Banco BPM, with a 20% premium in the exchange ratio and a €1bn special dividend. Its stake would rise from 29.6% to about 45%. BPM's CEO, Giuseppe Castagna, would lead the combined bank, which stays listed in Milan. Crédit Agricole targets €800m of annual synergies and 24% EPS accretion for BPM in 2027, with completion in the second half of 2027 (Crédit Agricole; Investing.com; Bloomberg).
• Banco BPM rose 10.7%, its biggest one-day gain in over four years; Italy's FTSE MIB rose 2.7% (CappNotes; Bloomberg).
• UniCredit rose about 4.7–6% after a record Q3: net profit rose 24% to €3.3bn (CNBC).

Moat and growth check: Italian bank consolidation creates scale advantages in a market that has been overbanked for years. The deal's structure is clever: it needs a two-thirds vote at BPM's meeting, with Crédit Agricole excluded, plus a waiver from the mandatory tender offer, ECB approval and likely a "golden power" review by Rome.

Is the market over- or under-reacting? Our view: BPM's 10.7% gain prices in about half the 20% premium. That makes sense given the political risk: Rome used its golden power over BPM before, and the Treasury declined to comment. BPM shareholders rejected MPS's offer in October, so they have shown they will say no.

Winners and losers: Winners: BPM shareholders, who get a premium and a dividend without giving up control to a foreign acquirer outright. Exposed: other Italian banks seeking scale (MPS, BPER), which now face a stronger competitor.

Luxury lags as China worries return

• LVMH fell about 2.1% to €400 and Hermès about 1.3% after Morgan Stanley cut its LVMH target to €415 (equal-weight). Its sector pick remains Richemont, which held roughly flat (MarketScreener; CNBC).
• CNBC cited inflation worries in China. China's PPI rose 5.7% and imports surged 41.6% in October, which is a cost pressure, not a demand boost, for luxury makers.
• Our view: Luxury did not join a risk-on rally with cheaper oil, which says investors still doubt a demand recovery. The split continues: Hermès and Richemont (jewelry) keep pricing power, while LVMH's fashion and leather business remains the weak spot.

Watch today

• US CPI (08:30 ET): consensus +0.3% m/m headline, +0.2% core, with no annual rate published. A December hike is about 80% priced. A hot core reading hurts small caps and long-duration growth stocks the most. Fed Governor Waller speaks (time not confirmed).
• TransDigm and On Holding earnings calls this morning (times not confirmed): watch TransDigm's pricing comments and M&A pipeline, and On's US demand and Q4 margin.
• CoreWeave (17:00 ET, after the close): a tech name, but its capex and funding plan matter for AI power suppliers (Caterpillar, GE Vernova, Constellation).
• Senate: floor debate continues on the permitting bill with data center cost-allocation rules.
• Wed 11 Nov: Veterans Day: the US bond market is closed; stocks trade. Siemens Energy reports fiscal Q4 results (press conference 02:00 ET). After the close: Corteva and Franco-Nevada.
• Thu 12 Nov: Siemens AG, Allianz and Munich Re (date per MarketScreener, unconfirmed) in Europe; Brookfield Corp. before the US open (call 10:00 ET).
• Fri 13 Nov: US PPI.

Sources

• CNBC — Stock market news for Nov. 9, 2026
• CNBC — Stocks making the biggest moves after hours, Nov. 9
• CNBC — Stocks making the biggest moves premarket, Nov. 10
• CappNotes — Closing Look, Monday, November 9, 2026
• Motley Fool — Stock market today, Nov. 9
• StockTitan — Stock market today, Nov. 9, 2026
• MarketScreener / Reuters — European shares near record high as lower oil prices boost sentiment
• Quartz — Anthropic agreed to pay $3.4 billion for gas generators
• Tom's Hardware — Anthropic takes over OnePWR's generator orders
• MLQ — Anthropic pays $3.4bn for 1.7 GW of Caterpillar generators, FT reports
• Yahoo Finance / GuruFocus — Caterpillar jumps 6.61% on Anthropic generator order
• TransDigm — Fiscal 2026 fourth quarter and year-end results
• Investing.com — TransDigm shares fall 4% on fiscal 2027 guidance miss
• WTOP / AP — TransDigm fiscal Q4 earnings snapshot
• GV Wire / Reuters — Berkshire accelerates buybacks, operating profit falls
• StockAnalysis — Berkshire Q3 operating earnings fall 5.8% as buybacks increase
• Finimize — Berkshire turned its cash pile into buybacks again
• SEC — KKR Q3 2026 earnings release
• SEC — Constellation Energy 8-K, 9 Nov 2026
• GuruFocus — Constellation Energy reports strong Q3, upgrades 2026 guidance
• Finviz — Constellation faces a credibility test on its raised 2026 outlook
• Tradingpedia — Constellation Energy jumps as earnings smash estimates
• CNN — FDA orders new eye risk warnings for Ozempic, Zepbound
• Bloomberg — FDA adds warning label to obesity drugs for eye condition
• Drugwatch — FDA requires NAION warning on all GLP-1 drugs
• Review of Optometry — GLP-1 drugs under scrutiny as lawsuits allege NAION risk
• Motley Fool — Eli Lilly is now worth nearly 9 Novo Nordisks
• MarketBeat — Healthcare stocks to watch, Nov. 9
• Hims & Hers — Third quarter 2026 results
• GuruFocus — Hims & Hers Q3 2026 results
• SEC — On Holding Q3 2026 press release (6-K)
• Investing.com — On Holding shares fall 5% premarket as tariff refund flatters Q3
• BioSpace — argenx to acquire Unnatural Products
• BioXconomy — argenx buys into macrocyclic peptides with $1.15bn deal
• Crédit Agricole — Proposal to Banco BPM to create a new leading Italian bank
• Investing.com — Crédit Agricole proposes Banco BPM merger, 20% premium and €1bn dividend
• Bloomberg — Crédit Agricole proposes merging local unit with Banco BPM
• MLQ — Crédit Agricole proposes merging its Italian unit with Banco BPM
• MarketScreener — Morgan Stanley cuts target prices for major luxury stocks
• Siemens Energy — Investor relations calendar
• Siemens — Financial calendar
• StockTitan — Earnings calendar for the week of November 9, 2026
• Market Chameleon — Earnings calendar
• Kiplinger — Earnings calendar, 9–13 Nov

Notes on method: Sector changes are SPDR ETF proxies from a single closing recap; the Motley Fool shows industrials at +4.59% instead of +3.82%. Caterpillar's Monday gain is +6.6% (GuruFocus) or +7.2% (CappNotes). Lilly's Monday move comes from pre-market (CNBC) and automated midday (MarketBeat) data, not a confirmed close. TransDigm's ~$25bn debt figure and the ~24x and ~22x multiples are our own estimates. Hims & Hers shows a −11.8% Monday move in one recap that conflicts with other reports and is not used.

Market analysis, not personal investment advice.